Terms: = Ovarian cancer AND LYL1, P12980, 4066, ENSG00000104903 AND Treatment
4 results:
1. PARP Inhibitors in ovarian cancer: A Trailblazing and Transformative Journey.
Konstantinopoulos PA; Matulonis UA
Clin Cancer Res; 2018 Sep; 24(17):4062-4065. PubMed ID: 29871906
[TBL] [Abstract] [Full Text] [Related]
2. FDA Approval Summary: Niraparib for the Maintenance treatment of Patients with Recurrent ovarian cancer in Response to Platinum-Based Chemotherapy.
Ison G; Howie LJ; Amiri-Kordestani L; Zhang L; Tang S; Sridhara R; Pierre V; Charlab R; Ramamoorthy A; Song P; Li F; Yu J; Manheng W; Palmby TR; Ghosh S; Horne HN; Lee EY; Philip R; Dave K; Chen XH; Kelly SL; Janoria KG; Banerjee A; Eradiri O; Dinin J; Goldberg KB; Pierce WF; Ibrahim A; Kluetz PG; Blumenthal GM; Beaver JA; Pazdur R
Clin Cancer Res; 2018 Sep; 24(17):4066-4071. PubMed ID: 29650751
[TBL] [Abstract] [Full Text] [Related]
3. [Umbilicus metastasis in patients with epithelial ovarian cancer : clinical features of 21 patients].
Xiao J; Li JD; Xu MM; Zhu AN; Feng YL
Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(25):1986-8. PubMed ID: 24169250
[TBL] [Abstract] [Full Text] [Related]
4. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study.
Poncelet C; Fauvet R; Yazbeck C; Coutant C; Darai E
Eur J Surg Oncol; 2010 Nov; 36(11):1066-72. PubMed ID: 20817462
[TBL] [Abstract] [Full Text] [Related]
